Science
Where Biology Meets Precision Design
Our science is rooted in deep biological insight and powered by de novo design. We develop breakthrough platform technologies and novel therapeutics to tackle some of the most complex, underserved challenges in brain health.
The BBB Breakthrough for Antibody Therapeutics
Conventional antibodies cannot normally enter the brain due to physical barrier known as the blood-brain barrier (BBB). The TRANSMAB platform transforms conventional antibodies into next-generation, BBB-penetrating antibodies by fusing multiple copies of de novo peptides selected from the TRANSPEP library. TRANSMAB antibodies are specifically designed to bind to the distinctive, densely clustered patterns of transferrin receptors expressed on brain capillaries, enabling effective penetration throughout the brain parenchyma.
TRANSMAB delivers superior brain pharmacokinetics without compromising systemic exposure, enabling brain-selective and efficient biodistribution.
Built on deep insight into TfR1 biology, TRANSMAB antibodies are spatially optimized to engage dense receptor clusters and drive efficient transcytosis.
TRANSMAB is designed to preserve TfR1 expression, minimizing reticulocyte reduction and reducing hematological toxicity for a superior safety profile.
We harness the synergy of de novo design, structural biology, and directed evolution to craft hypercompact, stable protein binders targeting the transferrin receptor.
The TRANSPEP library comprises de novo peptides with diverse affinities and properties, enabling multivalent fusion to conventional antibodies and precise control of avidity.
